Sirolimus (SRL) is widely used to prevent restenosis after
percutaneous coronary intervention. However, its beneficial effect is hampered by complications of
thrombosis. Several studies imply that
reactive oxygen species (ROS) play a critical role in endothelial dysfunction and
thrombus formation. The present study investigated the protective effect of
nicorandil (NIC), an anti-angina agent, on SRL-associated
thrombosis. In human coronary artery endothelial cells (HCAECs), SRL stimulated ROS production, which was prevented by co-treatment with NIC. The preventive effect of NIC on ROS was abolished by
5-hydroxydecanoate but not by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. NIC also inhibited SRL-induced up-regulation of
NADPH oxidase subunit p22(
phox)
mRNA. Co-treatment with NIC and SRL significantly up-regulated
superoxide dismutase 2. NIC treatment significantly improved SRL-induced decrease in viability of HCAECs. The functional relevance of the preventive effects of NIC on SRL-induced ROS production and impairment of endothelial viability was investigated in a mouse model of
thrombosis. Pretreatment with NIC inhibited the SRL-induced acceleration of FeCl3-initiated
thrombus formation and ROS production in the testicular arteries of mice. In conclusion, NIC prevented SRL-induced
thrombus formation, presumably due to the reduction of ROS and to endothelial protection. The therapeutic efficacy of NIC could represent an additional option in the prevention of SRL-related
thrombosis.